The lowest risk of hypoglycemia and insulin-sensitizing effect seen with pioglitazone makes it an attractive option for treating elderly type 2 diabetes patients, regardless of whether they are combined with new-generation OHA. This evidence concerns the gene INS and type 2 diabetes mellitus.